Brokerages Set Invivyd, Inc. (NASDAQ:IVVD) PT at $8.00

Shares of Invivyd, Inc. (NASDAQ:IVVD) have been assigned an average rating of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $8.00.

IVVD has been the topic of a number of research reports. Wall Street Zen cut Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Thursday, May 14th. Finally, BTIG Research reiterated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Monday, May 18th.

Institutional Trading of Invivyd

Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its stake in Invivyd by 152.9% during the 1st quarter. Bank of America Corp DE now owns 962,386 shares of the company’s stock valued at $1,251,000 after purchasing an additional 581,782 shares during the period. Stempoint Capital LP increased its stake in shares of Invivyd by 89.4% in the first quarter. Stempoint Capital LP now owns 1,874,546 shares of the company’s stock valued at $2,437,000 after purchasing an additional 884,724 shares during the period. Janus Henderson Group PLC raised its holdings in shares of Invivyd by 1.7% during the first quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock valued at $42,857,000 after buying an additional 551,188 shares during the last quarter. Eversept Partners LP raised its holdings in shares of Invivyd by 6.4% during the first quarter. Eversept Partners LP now owns 2,276,349 shares of the company’s stock valued at $2,959,000 after buying an additional 136,219 shares during the last quarter. Finally, SummitTX Capital L.P. acquired a new position in shares of Invivyd during the first quarter worth approximately $37,000. 70.36% of the stock is currently owned by institutional investors.

Invivyd Stock Performance

NASDAQ IVVD opened at $1.10 on Wednesday. Invivyd has a one year low of $0.48 and a one year high of $3.07. The company has a 50-day simple moving average of $1.42 and a 200-day simple moving average of $1.87. The firm has a market capitalization of $324.07 million, a PE ratio of -3.55 and a beta of 0.71.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, May 14th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.08) by ($0.05). Invivyd had a negative return on equity of 53.48% and a negative net margin of 138.90%.The business had revenue of $13.74 million for the quarter, compared to analyst estimates of $18.04 million. Equities analysts forecast that Invivyd will post -0.5 earnings per share for the current year.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.